Zinetac Tablets (Generic Zantac) - Active Ingredient And Chemical structure
The active ingredient contained in Zinetac Tablets is Ranitidine Hydrochloride. Ranitidine HCl is a white to pale yellow, granular substance that is soluble in water. It has a slightly bitter taste and sulfur like odour.The structure is shown below
Generic Zantac (Ranitidine HCl) - Uses
Generic Zantac in the form of Zinetac Tablets is used for the:
1.Short term treatment of active duodenal ulcer. Most patients undergoing treatment heal within 4 weeks of Zinetac therapy.
2.Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
3.The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis).
4.Short term treatment of active, benign gastric ulcer. Most patients undergoing treatment heal within 6 weeks.
5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers.
6. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Zinetac 150 mg twice a day.
7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Zinetac 150 mg four times a day.
8. Maintenance of healing of erosive esophagitis.
Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis.
Generic Forms and Brand names of Zantac (Ranitidine HCl)
Zinetac Tablets manufactured by GlaxoSmithKline, India is an effective treatment for the conditions that cause your body to make too much stomach acid. Zantac which has the active ingredient Ranitidine Hydrochloride is also sold under various other brand names.
Zinetac Tablets (Generic Zantac) - Preparations
Zinetac Tablets is available as tablets of 150 mg and 300 mg . Each Zinetac 150 mg Tablet for oral administration contains 168 mg of ranitidine HCl equivalent to 150 mg of ranitidine.
Zinetac Tablets (Generic Zantac) - Storage Requirements
Zinetac Tablets are to be stored at room temperature (15°C to 30°C). Store away from heat, moisture, and light. Keep away from children and pets.
Zinetac Tablets (Generic Zantac) - Dosage
The recommended dosage for the various conditions being treated is given below. Please consult your doctor for exact dosing instructions.
Active Duodenal Ulcer: The recommended adult oral dosage of Zinetac Tablets for duodenal ulcer is 150 mg twice daily.
Maintenance of Healing of Duodenal Ulcers: The recommended adult oral dosage is 150 mg at bedtime.
Pathological Hypersecretory Conditions (such as Zollinger-Ellison syndrome): The recommended adult oral dosage is 150 mg twice a day.
Benign Gastric Ulcer: The current recommended adult oral dosage is 150 mg twice a day.
Maintenance of Healing of Gastric Ulcers: The current recommended adult oral dosage is 150 mg at bedtime.
GERD: The current recommended adult oral dosage is 150 mg twice a day.
Erosive Esophagitis: The current recommended adult oral dosage is 150 mg 4 times a day.
Maintenance of Healing of Erosive Esophagitis: The current recommended adult oral dosage is 150 mg twice a day.
Zinetac Tablets (Generic Zantac) - Contraindications
Zinetac Tablets is contraindicated for patients known to have hypersensitivity to Ranitidine Hydrochloride or any inactive ingredient present in the medication.
Side Effects Of Zinetac Tablets (Generic Zantac)
The most common side effects of Zinetac Tablets (Ranitidine HCl) are
Central Nervous System: Rarely, malaise, dizziness, somnolence, insomnia, and vertigo. Rare cases of reversible mental confusion, agitation, depression, and hallucinations have been reported, predominantly in severely ill elderly patients. Rare cases of reversible blurred vision as well as of reversible involuntary motor disturbances have also been received.
Cardiovascular: As with other H2-blockers, rare reports of arrhythmias such as tachycardia, bradycardia, atrioventricular block, and premature ventricular beats.
Gastrointestinal: Constipation, diarrhea, nausea/vomiting, abdominal discomfort/pain, and rare reports of pancreatitis.
Hepatic: There have been occasional reports of hepatocellular, cholestatic, or mixed hepatitis, with or without jaundice. In such circumstances, ranitidine should be immediately discontinued. These events are usually reversible, but in rare circumstances death has occurred. Rare cases of hepatic failure have also been reported.
Musculoskeletal: Rare reports of arthralgias and myalgias.
Hematologic: Blood count changes (leukopenia, granulocytopenia, and thrombocytopenia) that were usually reversible have occurred in a few patients. There were rare cases of agranulocytosis, pancytopenia, sometimes with marrow hypoplasia, and aplastic anemia and exceedingly rare cases of acquired immune hemolytic anemia that have been reported.
Endocrine: Controlled studies in animals and man have shown no stimulation of any pituitary hormone by Ranitidine HCl and no antiandrogenic activity, and cimetidine-induced gynecomastia and impotence in hypersecretory patients have resolved when Zinetac has been substituted. However, occasional cases of gynecomastia, impotence, and loss of libido have been reported in male patients receiving Zinetac , but the incidence did not differ from that in the general population.
Integumentary: Rash, including rare cases of erythema multiforme. Rare cases of alopecia and vasculitis.
Other Side Effects: The other side effects reported with Zinetac (Ranitidine HCl) use are Rare cases of hypersensitivity reactions (e.g., bronchospasm, fever, rash, eosinophilia), anaphylaxis, angioneurotic edema, and small increases in serum creatinine.
